Polyrizon (PLRZ) said Friday that it has signed a non-binding letter of intent with an unidentified company specializing in psychedelic-based therapies to develop a novel intranasal formulation using Polyrizon's proprietary platform to improve the delivery of psychedelic treatments.
Polyrizon said it will develop the formulation using its mucoadhesive technology, while the psychedelic-focused company will fund the research and development, including feasibility studies.
After establishing proof of concept, both parties intend to finalize a definitive agreement on intellectual property, royalties, commercialization rights, and financial terms, Polyrizon said.
Shares of the company were down nearly 20% in recent premarket activity on Friday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。